secwatch.observer — SEC 8-K summary
======================================

Issuer:     Annexon, Inc. (ANNX)
CIK:        0001528115
Form:       8-K
Filed at:   2023-12-20T23:59:59+00:00
Accession:  0001193125-23-300035
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA aligns with Annexon on vision preservation endpoint for ANX007 GA Phase 3 program; ANX1502 Ph1 positive
--------------------------------------------------------------------------------

- FDA agrees to prevention of ≥15-letter BCVA loss as primary endpoint; no requirement for surrogate structural endpoint.
- Two Phase 3 trials: ARCHER II (sham-controlled, ~400 pts, starts mid-2024) and ARROW (head-to-head vs Syfovre, ~500 pts, starts late 2024).
- ANX007 Phase 2 ARCHER showed 72% risk reduction (p=0.006) in BCVA ≥15-letter loss in monthly dose arm vs sham.
- ANX1502 Phase 1 healthy-volunteer data: target drug levels with BID dosing, suppressed C4d biomarker, no serious AEs.
- Company plans to advance tablet formulation of ANX1502 into proof-of-concept trial in CAD patients in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1528115/000119312523300035/0001193125-23-300035-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1528115/000119312523300035/d649765d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-300035

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer